Top Page
Joint
(NASDAQ:JYNT)
Joint (JYNT) vs. SPDR S&P 500 ETF (SPY)
Joint Business Overview & Revenue Model
Joint Earnings Call Summary
Joint Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 51.90M | 117.70M | 101.91M | 81.19M | 58.68M |
| Gross Profit | 40.38M | 107.15M | 92.08M | 72.68M | 52.18M |
| EBITDA | 2.98M | 9.14M | 7.89M | 12.16M | 8.18M |
| Net Income | -8.53M | -9.75M | 1.18M | 7.57M | 13.17M |
Balance Sheet | |||||
| Total Assets | 80.42M | 87.15M | 91.94M | 84.04M | 65.73M |
| Cash, Cash Equivalents and Short-Term Investments | 25.05M | 18.15M | 9.75M | 19.53M | 20.55M |
| Total Debt | 448.29K | 16.73M | 26.06M | 22.45M | 18.48M |
| Total Liabilities | 62.48M | 62.38M | 59.54M | 54.48M | 44.98M |
| Stockholders Equity | 17.92M | 24.75M | 32.37M | 29.54M | 20.75M |
Cash Flow | |||||
| Free Cash Flow | 8.23M | 9.68M | 2.31M | 6.85M | 6.99M |
| Operating Cash Flow | 9.42M | 14.68M | 11.08M | 15.23M | 11.18M |
| Investing Cash Flow | -631.55K | -6.19M | -20.78M | -14.14M | -4.60M |
| Financing Cash Flow | -2.00M | 174.12K | 328.61K | -2.00M | 5.60M |
Joint Technical Analysis
Joint Risk Analysis
Joint Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | $1.49B | 13.95 | 11.19% | 2.61% | 19.16% | 31.92% | |
73 Outperform | $1.11B | 30.07 | 5.00% | ― | 54.81% | -45.07% | |
67 Neutral | $1.09B | 32.37 | 6.72% | 2.54% | 14.30% | 76.89% | |
53 Neutral | $363.98M | ― | -227.77% | ― | 17.64% | 13.86% | |
51 Neutral | kr5.99B | 9.30 | -57.89% | 2.12% | 23.80% | 21.79% | |
51 Neutral | $171.24M | ― | -27.25% | ― | -26.14% | 23.04% | |
48 Neutral | $37.18M | ― | -951.52% | ― | -0.70% | -2.38% |
Joint Corporate Events
On June 30, 2025, The Joint Corp. completed the sale of 31 company-owned clinics in Arizona and New Mexico to Joint Ventures, LLC for $8.3 million and acquired regional developer rights in the Northwest Region. This transaction is part of The Joint Corp.’s strategy to strengthen and simplify its business by transferring clinics to proven franchise operators, while acquiring regional developer rights to reduce commission obligations and increase operating margins, thus enhancing value for stakeholders.
The most recent analyst rating on (JYNT) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.
On June 23, 2025, The Joint Corp. entered into an Asset Purchase Agreement with Joint Ventures, LLC to sell 31 company-owned clinics in Arizona and New Mexico for $11.07 million. This transaction, expected to close by June 30, 2025, also involves acquiring regional developer rights in the Northwest Region, which includes 46 existing franchised clinics and 30 future development sites. Additionally, The Joint Corp. refranchised five clinics in Kansas and Missouri to Chiro 93, LLC. These strategic moves aim to enhance The Joint’s profitability and solidify its position as the largest pure play chiropractic care franchise system.
The most recent analyst rating on (JYNT) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.
On June 10, 2025, The Joint Corp. announced the appointment of Scott J. Bowman as its new Chief Financial Officer, succeeding Jake Singleton. Bowman, who brings over 30 years of experience in finance, has previously served as CFO at several public companies, including Leslie’s, Inc. and Dave & Buster’s. His expertise in capital markets and strategic planning is expected to support The Joint Corp.’s strategy to reignite growth and improve profitability. The company aims to transform into a pure play franchisor and enhance its position as a leading health and wellness services provider in the U.S.
The most recent analyst rating on (JYNT) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.
On June 3, 2025, The Joint Corp.’s Board of Directors expanded its size and appointed Sandi Karrmann as a new director, who will also serve as Chair of the Compensation Committee. Karrmann, with extensive experience in human resources and healthcare, is expected to contribute to the company’s strategic goals of enhancing talent and culture to boost growth and profitability. Additionally, the Board approved a stock repurchase plan to buy back up to $5 million of common stock by June 2027, aiming to optimize capital structure and enhance shareholder value.
The most recent analyst rating on (JYNT) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.
On May 21, 2025, Joint company held its annual meeting of stockholders where several key decisions were made. The election of seven directors to the Board was confirmed, with each nominee receiving the necessary votes to serve until the next annual meeting in 2026. Additionally, the compensation of named executive officers was approved, and the appointment of BDO USA, P.C. as the independent registered public accounting firm for the year ending December 31, 2025, was ratified.
The most recent analyst rating on (JYNT) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.
On May 8, 2025, The Joint Corp. reported its financial results for the first quarter of 2025, showing a 7% increase in revenue from continuing operations to $13.1 million compared to the same period in 2024. Despite a net loss from continuing operations of $506,000, the company demonstrated economic resilience with a 5% increase in system-wide sales to $132.6 million. The company is undergoing a transition to become a pure-play franchisor, implementing new marketing and operational strategies to enhance growth and profitability. The Joint Corp. expects system-wide sales to reach between $550 million and $570 million in 2025, with new franchised clinic openings projected between 30 and 40.